logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10046041 B1

PDFFull Text
Date of Patent:
Aug. 14, 2018

Filed:

Dec. 22, 2016

[object object]

Applicant:

Microvax, Llc, Warrenton, VA (US);

Inventor:

Albert B. Deisseroth, Potomac, MD (US);

Assignee:

MicroVAX, LLC, Warrenton, VA (US);

Attorneys:

Jacob Frank

Glenn Snyder

Primary Examiner:

Padmavathi Baskar

Int. Cl.
CPC ...
A61K 9/00 (2006.01); C07K 14/31 (2006.01); C12N 9/50 (2006.01); C07K 14/70 (2006.01); A61K 39/085 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/085 (2013.01); A61K 9/0019 (2013.01); C07K 14/31 (2013.01); C07K 14/70539 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C12N 7/00 (2013.01); C12N 9/50 (2013.01); C12Y 304/23 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6031 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C12N 2710/10043 (2013.01);
Abstract

The present invention is directed to methods of suppressing the virulence of one or more virulence antigenic factors of methicillin resistant(MRSA). Aspects of the invention include administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of a virulence antigenic factor of MRSA attached through a linker to the aminoterminal end of the ecd CD40 ligand. The fusion protein is composed of a virulence antigenic factor of MRSA and CD40 ligand and has the ability to generate antibodies which prevents host cell infection by suppressing virulence functions of MRSA.

Find Patent Forward Citations

Loading…